^
    2d
    A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=104, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting
    Enrollment closed • Minimal residual disease
    |
    CD19 (CD19 Molecule)
    2d
    E-STOP2: Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia (clinicaltrials.gov)
    P4, N=136, Not yet recruiting, Hospital Universitari Vall d'Hebron Research Institute
    New P4 trial
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    3d
    NCI-2018-01752: Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)
    P2, N=68, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2027 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • methotrexate • fludarabine IV • thiotepa • busulfan • methotrexate IV
    3d
    ALT-101: First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect. (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Allterum Therapeutics, Inc
    New P1 trial • First-in-human
    3d
    Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia Treatment (clinicaltrials.gov)
    P=N/A, N=621, Completed, University of Southern Denmark | Active, not recruiting --> Completed | Trial primary completion date: Apr 2025 --> Oct 2025
    Trial completion • Trial primary completion date
    4d
    KOMET-001: First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=263, Active, not recruiting, Kura Oncology, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • First-in-human
    |
    NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A) • MEIS1 (Meis Homeobox 1)
    |
    NPM1 mutation • KMT2A rearrangement
    |
    Komzifti (ziftomenib) • Onmel (itraconazole) • Tolsura (SUBA-itraconazole)
    4d
    ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL (clinicaltrials.gov)
    P=N/A, N=92, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting | N=30 --> 92
    Enrollment open • Enrollment change • IO biomarker
    |
    ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase)
    |
    Venclexta (venetoclax) • cytarabine • Jakafi (ruxolitinib) • cyclophosphamide • Blincyto (blinatumomab) • Nailike (olverembatinib) • fludarabine IV
    4d
    Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=53, Terminated, M.D. Anderson Cancer Center | Trial completion date: Dec 2026 --> May 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2026 --> May 2026; <75% participation
    Trial completion date • Trial termination • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • Oncaspar liquid (pegaspargase) • Truxima (rituximab-abbs) • nelarabine • Starasid (cytarabine ocfosfate)
    4d
    Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL (clinicaltrials.gov)
    P=N/A, N=110, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    ABL1 (ABL proto-oncogene 1) • BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • cytarabine • Blincyto (blinatumomab) • Nailike (olverembatinib)
    4d
    CAR-p40-T: Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=10, Recruiting, Shenzhen University General Hospital
    New P1/2 trial
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    5d
    Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies (clinicaltrials.gov)
    P1/2, N=124, Terminated, Sun Pharma Advanced Research Company Limited | Active, not recruiting --> Terminated; Closed for administrative, non-safety-related reasons.
    Trial termination
    |
    vodobatinib (SCO - 088)
    5d
    Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, Novartis Pharmaceuticals | Initiation date: Mar 2026 --> Jul 2026
    Trial initiation date
    |
    ABL1 (ABL proto-oncogene 1) • CD19 (CD19 Molecule)
    |
    ABL1 T315I • ABL2 fusion
    |
    cytarabine • Blincyto (blinatumomab) • vincristine • Scemblix (asciminib)